Thus, fracture risk stratification in T2D should first rely on the presence of fragility fractures (including the identification of morphometric vertebral fractures), as well as on specific risk factors, such as the duration of disease, glycemic control, ongoing treatments for T2D (e.g., insulin or thiazolidinediones), and the presence of typical T2D complications [2,131]. This evidence concerns the gene INS and type 2 diabetes mellitus.